The overall goal of this research is to improve 1) methadone maintenance therapy, the cornerstone of opiate abuse treatment and a vitally effective strategy for HIV/AIDS risk reduction, 2) the safety and effectiveness of methadone when used for pain treatment, and 3) the treatment of HIV/AIDS. Methadone disposition is characterized by unexplained and unpredictable variability, causing opiate withdrawal, toxicity, and treatment failures. Increased methadone use for pain treatment has been accompanied by an epidemic of adverse reactions, particularly in the early weeks of therapy. Highly active antiretroviral therapy for HIV/AIDS causes clinically significant, complex, and insufficiently understood drug interactions. Methadone-anti retroviral drug interactions are clinically significant but poorly understood, and not predictable based on present knowledge. Both pharmacokinetic and pharmacodynamic interactions can occur. The proposed research challenges the longstanding notion that cytochrome P4503A is responsible for clinical methadone metabolism and drug interactions. Antiretroviral interactions which inhibit drug metabolism generally are well understood, however those which up regulate metabolism remain poorly understood. Pharmacodynamic interactions suggest a role for drug transporters in brain methadone disposition, but these transporter(s) are presently unknown.
The aims of this research program are to definitively elucidate enzymes and mechanisms of both hepatic and renal methadone clearance, the influence of anti retroviralson the enzymes and transporters mediating methadone disposition, and the role of drug transporters in methadone pharmacodynamics and clinical effects, and the influence of antiretrovirals on those critical pathways. A concerted clinical and translational approach to these aims will be pursued. A series of complementary laboratory-based and clinical studies are planned for each aim, combining novel cellular models of metabolism and transport with comprehensive mechanistically-driven and therapeutically applicable clinical protocols in healthy subjects and patients. Clinical studies will use novel in vivo probes and methods for determining method one brain disposition and pharmacodynamics. Successful completion of the aims will provide fundamental new information on methadone disposition, improve methadone therapeutic guidance and safety, and enhance the treatments and outcomes of opiate addiction, pain and HIV/AIDS.

Public Health Relevance

The proposed research is relevant to the significant public health problems of HIV/AIDS, substance abuse, drug interactions, appropriate treatment of pain, inappropriate use of prescriptionopioid pain medications, and the rising incidence of serious adverse complications from pain treatment. It is also relevant to creating a better basic understanding of how drugs enter the brain and are inactivated by the body, and how therapeutic drugs affect healthy and ill individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA014211-11
Application #
8308554
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Khalsa, Jagjitsingh H
Project Start
2001-04-01
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
11
Fiscal Year
2012
Total Cost
$561,637
Indirect Cost
$192,139
Name
Washington University
Department
Anesthesiology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Teitelbaum, A M; Murphy, S E; Akk, G et al. (2018) Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. Pharmacogenomics J 18:136-143
Hicks, J K; Sangkuhl, K; Swen, J J et al. (2017) Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102:37-44
Kharasch, Evan D (2017) Current Concepts in Methadone Metabolism and Transport. Clin Pharmacol Drug Dev 6:125-134
Teitelbaum, Aaron M; Kharasch, Evan D (2016) Misidentification of Bupropion Glucuronide Metabolites and Re-evaluation of Metabolite Pharmacokinetics. Drug Metab Dispos 44:1851
Teitelbaum, Aaron M; Flaker, Alicia M; Kharasch, Evan D (2016) Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 1027:239-53
Lenze, Eric J; Farber, Nuri B; Kharasch, Evan et al. (2016) Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial. World J Biol Psychiatry 17:230-8
Horst, Jennifer; Frei-Jones, Melissa; Deych, Elena et al. (2016) Pharmacokinetics and analgesic effects of methadone in children and adults with sickle cell disease. Pediatr Blood Cancer 63:2123-2130
Kharasch, Evan D; Brunt, L Michael (2016) Perioperative Opioids and Public Health. Anesthesiology 124:960-5
Teitelbaum, Aaron M; Flaker, Alicia M; Kharasch, Evan D (2016) Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 1017-1018:101-113
Kharasch, Evan D; Eisenach, James C (2016) Wherefore Gabapentinoids?: Was There Rush Too Soon to Judgment? Anesthesiology 124:10-2

Showing the most recent 10 out of 68 publications